Pharmacodynamic effects of daclizumab in the intrathecal compartment.

ABSTRACT:

Objective

It was previously demonstrated that daclizumab therapy normalizes cellular cerebrospinal fluid (CSF) abnormalities typical of multiple sclerosis (MS) in the majority of treated patients. However, CSF cells represent only the mobile portion of intrathecal immune responses. Therefore, we asked whether daclizumab also reverses compartmentalized inflammation and if not, whether residual inflammation correlates with clinical response to the drug.

Methods

Forty MS patients treated with an intravenous or subcutaneous injection of daclizumab were followed for up to 16 years in two open-label clinical trials. MRI contrast-enhancing lesions (CELs), clinical scales, and CSF biomarkers quantified residual disease.

Results

Rapid decreases in CELs, sustained throughout th

SUBMITTER: Komori M 

PROVIDER: S-EPMC5497534 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature